UPDATED May 01, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$776.75 | 6.1% | 80.1% | US$703.3b | US$845.32 | PE113.9x | E27.2% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$484.11 | -0.7% | -1.1% | US$445.0b | US$567.36 | PE29x | E19.1% | 1.6% | Healthcare | ||
JNJ | US$151.18 | 1.8% | -7.2% | US$348.4b | US$173.26 | PE19x | E5.1% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$128.80 | 1.4% | 8.9% | US$327.3b | US$141.31 | PE141.5x | E25.6% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$161.72 | -3.6% | 8.4% | US$288.0b | US$182.65 | PE48.1x | E23.2% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£121.70 | 1.2% | 2.7% | UK£188.7b | UK£131.45 | PE37.3x | E16.5% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$574.99 | -0.4% | 4.5% | US$217.1b | US$623.11 | PE36.4x | E11.9% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$106.29 | -0.6% | -4.9% | US$183.9b | US$126.33 | PE32.9x | E11.3% | 2.1% | Healthcare | ||
DHR | US$246.89 | -1.4% | 0.5% | US$182.7b | US$269.86 | PE44.9x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$277.37 | 3.0% | 19.6% | US$148.8b | US$303.26 | PE22.1x | E9.0% | 3.2% | Pharmaceuticals & Biotech | ||
PFE | US$27.18 | 3.5% | -29.3% | US$145.1b | US$31.62 | PE72.1x | E21.9% | 6.2% | Pharmaceuticals & Biotech | ||
ISRG | US$371.70 | -0.9% | 21.8% | US$131.5b | US$420.59 | PE66.3x | E11.6% | n/a | Healthcare | ||
SYK | US$328.12 | -2.6% | 14.3% | US$128.0b | US$371.92 | PE37.1x | E12.4% | 1.0% | Healthcare | ||
ELV | US$524.84 | -1.7% | 14.5% | US$122.9b | US$599.48 | PE19.5x | E12.5% | 1.2% | Healthcare | ||
MDT | US$80.89 | 0.6% | -10.8% | US$106.5b | US$94.75 | PE25.6x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.21 | -1.0% | 37.0% | US$105.6b | US$80.66 | PE60.1x | E18.2% | n/a | Healthcare | ||
VRTX | US$402.14 | 0.3% | 16.1% | US$101.5b | US$459.72 | PE28.7x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
CI | US$357.18 | 1.4% | 45.2% | US$101.3b | US$381.44 | PE19.6x | E9.6% | 1.6% | Healthcare | ||
REGN | US$903.48 | -0.3% | 12.5% | US$96.1b | US$1,038.08 | PE24.7x | E11.2% | n/a | Pharmaceuticals & Biotech | ||
BMY | US$44.21 | -9.5% | -33.7% | US$89.1b | US$53.54 | PS2x | E43.0% | 5.4% | Pharmaceuticals & Biotech | ||
GSK | UK£17.05 | 3.9% | 16.3% | UK£69.5b | UK£20.20 | PE15.5x | E11.3% | 3.4% | Pharmaceuticals & Biotech | ||
CSL | AU$275.39 | -1.1% | -8.2% | AU$132.6b | AU$306.40 | PE35.2x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
CVS | US$56.31 | -16.9% | -19.6% | US$85.3b | US$85.84 | PE9.7x | E10.4% | 4.7% | Healthcare | ||
HCA | US$309.44 | -3.0% | 11.2% | US$81.9b | US$343.58 | PE15x | E6.0% | 0.9% | Healthcare |